- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 23.01. | INTENSITY THERAPEUTICS, INC. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 13.01. | Intensity Therapeutics legt nach klinischer Validierung Strategie für 2026 fest | 5 | Investing.com Deutsch | ||
| 13.01. | Intensity Therapeutics Inc.: Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities | 188 | PR Newswire | Peer-reviewed clinical validation, strengthened balance sheet, and disciplined execution position the Company for 2026
SHELTON, Conn., Jan. 13, 2026 /PRNewswire/... ► Artikel lesen | |
| 05.12.25 | Intensity Therapeutics receives 180-day Nasdaq extension to regain compliance | 12 | Seeking Alpha | ||
| 05.12.25 | Intensity Therapeutics gets 180-day extension to meet Nasdaq price rule | 1 | Investing.com | ||
| 04.12.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.11.25 | Intensity Therapeutics GAAP EPS of -$0.06 in-line | 8 | Seeking Alpha | ||
| 06.11.25 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | 134 | PR Newswire | The Company expects to file a protocol amendment in the INVINCIBLE-4 Study to revise the dosing regimen for the INT230-6 treatment cohort, and to reinitiate... ► Artikel lesen | |
| 06.11.25 | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 31.10.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 31.10.25 | Intensity Therapeutics announces pricing of $4M registered direct offering of common stock | 11 | Seeking Alpha | ||
| 31.10.25 | Kapitalerhöhung mit hohem Abschlag: Aktie von Intensity Therapeutics stürzt ab | 16 | Investing.com Deutsch | ||
| 31.10.25 | Intensity Therapeutics stock tumbles after pricing $4 million offering | 3 | Investing.com | ||
| 31.10.25 | Intensity Therapeutics sichert sich 4 Millionen US-Dollar durch registrierte Direktplatzierung | 11 | Investing.com Deutsch | ||
| 31.10.25 | Intensity Therapeutics prices $4 million registered direct offering | 1 | Investing.com | ||
| 31.10.25 | Intensity Therapeutics Stock Cools After-Hours Following 395% Surge: What You Should Know | 14 | Benzinga.com | ||
| 30.10.25 | Intensity Therapeutics stock soars after phase 1/2 data publication | 10 | Investing.com | ||
| 30.10.25 | Intensity Therapeutics publishes cancer treatment study results in Lancet journal | 27 | Investing.com | ||
| 23.10.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 11 | SEC Filings | ||
| 10.09.25 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 3 | SEC Filings |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,40 | +0,17 % | Startschuss! BioTech-Sektor profitiert von Rotation! Augen auf bei Evotec, Bayer, Vidac Pharma and BioNTech | Mit positiver Grundstimmung hat die Börse das Jahr 2026 eingeläutet. Dass Renditechancen nicht allein im Technologiesektor liegen, bewies zuletzt der Minen- und Rohstoffbereich, wo etliche Titel Kursverdopplungen... ► Artikel lesen | |
| NOVAVAX | 6,910 | -0,80 % | Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln | NEW YORK CITY (dpa-AFX) - Novavax, Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer, Inc. (PFE) for use of Novavax's Matrix-M adjuvant. Under the terms... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,200 | -0,48 % | Morningstar, Inc.: Morningstar Completes Acquisition of CRSP and Extends Relationship with Vanguard | The CRSP integration unites two trusted sources of market insight, reinforcing a shared commitment to transparency, quality, and investor-focused solutions and solidifying Morningstar's position... ► Artikel lesen | |
| EDITAS MEDICINE | 1,536 | +0,03 % | Editas Medicine, Inc.: Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate | EDIT-401 achieved ~90% mean LDL-C reduction with single dose in non-human primates EDIT-401 on track for human proof-of-concept data by end of 2026 Strong cash position with operational runway into... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,600 | +0,58 % | OpenAI und Ginkgo Bioworks optimieren Proteinsynthese mit GPT-5 im Roboterlabor | ||
| IOVANCE BIOTHERAPEUTICS | 2,114 | -1,45 % | Iovance Biotherapeutics, Inc.: Best-in-Class Real-World Data Support Early Amtagvi Treatment in Advanced Melanoma | SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal... ► Artikel lesen | |
| NOVOCURE | 8,690 | +1,35 % | Novocure-Aktie stürzt ab: US-Gesundheitsbehörde entzieht Abrechnungsbefugnis | ||
| ADAPTIMMUNE THERAPEUTICS | 0,016 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| MACROGENICS | 1,457 | -4,58 % | MacroGenics, Inc.: MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress | Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics' novel T-cell engager platformRealigned... ► Artikel lesen | |
| SPERO THERAPEUTICS | 2,030 | 0,00 % | Anterix Inc.: Anterix Appoints Ross Spero as Chief Product Officer | WOODLAND PARK, N.J., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Anterix, Inc. (NASDAQ: ATEX) today announced the appointment of Ross Spero as Chief Product Officer. Spero will lead Anterix's product development... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 15,510 | +5,01 % | MoonLake Immunotherapeutics AG: MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day | The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive... ► Artikel lesen | |
| X4 PHARMACEUTICALS | 2,450 | -100,00 % | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| KORRO BIO | 12,570 | +8,93 % | Korro Bio stock rating upgraded by H.C. Wainwright to Buy on new drug potential | ||
| NEUMORA THERAPEUTICS | 2,125 | +8,42 % | Neumora Therapeutics, Inc.: Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 | ||
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
INTENSITY THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,355 Euro und damit +5,12 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.